Global monitoring of cross-resistance between tigecycline and minocycline, 2004-2009

Journal of Infection

Volumn 60, Issue 5, 2010, Pages 401-402

  Hawser, Stephen P ^a  

^a International Health Management Associates Europe Sàrl   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; EXTENDED SPECTRUM BETA LACTAMASE; MINOCYCLINE; TIGECYCLINE;

ACINETOBACTER BAUMANNII; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BROTH DILUTION; CROSS RESISTANCE; DRUG BINDING; DRUG EFFICACY; DRUG MONITORING; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MINOCYCLINE;

EID: 77952549531     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.03.001     Document Type: Letter

References (8)

1. Fraise A.P. Tigecycline: the answer to beta-lactama nd fluoroquinolone resistance. Journal of Infection 2006, 53:293-300.
2. Poulaku G., Kontopidou F.V., Paramythiotou E., Kompoti M., Katsiari M., Mainas E., et al. Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens. Journal of Infection 2009, 58:273-284.
3. Nicolau D.P. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. 2009. Expert Opinion in Pharmacotherapy 2009, 10:1213-1222.
4. Clinical Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition, in document M7-A7 2007, Clinical Laboratory Standards Institute (CLSI), 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA.
5. Clinical Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing, in document M100-S19 2009, Clinical Laboratory Standards Institute (CLSI), 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA.
6. ® FDA product information 2009, http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021821s013s017s018lbl.pdf.
7. Bishburg E., Bishburg K. Minocycline-an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. International Journal of Antimicrobial Agents 2009, 34:395-401.
8. Olson M.W., Ruzin A., Feyfant E., Rush T.S., O'Connell J., Bradford P.A. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrobial Agents and Chemotherapy 2006, 50:2156-2166.